Evaluation the effectiveness of rivastigmine and memantine in improving cognitive problems due to electroconvulsive therapy
Phase 3
Recruiting
- Conditions
- Psychiatric disorders with electroconvulsive therapy (ECT) indication.
- Registration Number
- IRCT20190119042417N2
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Being in the age range of 18-60 years.
Being a candidate to receive electroconvulsive therapy.
Collaborate to perform Montreal cognitive assessment.
Having informed consent to participate in the study.
Exclusion Criteria
History of neurocognitive disorders such as delirium and dementia
History of cardiac conductive disorder and arrhythmia
History of hepatic, renal, thyroid, and seizure disorders
History of sensitivity to rivastigmine and memantine
History of electroconvulsive therapy within the the past 6 months
Taking calcium channel blockers and cox-inhibitors
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cognitive impairment. Timepoint: One day before starting ECT, 2 and 6 weeks after starting ECT. Method of measurement: Montreal Cognitive Scale (MOCA).
- Secondary Outcome Measures
Name Time Method